Drug Profile
Research programme: MCL-1 protein inhibitors - Calithera Biosciences
Alternative Names: MCL-1 Program - Calithera BiosciencesLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Calithera Biosciences
- Class Small molecules
- Mechanism of Action MCL1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 29 Oct 2013 Preclinical trials in Cancer in USA (unspecified route)